Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to report earnings of ($0.16) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mediwound’s earnings, with estimates ranging from ($0.17) to ($0.14). Mediwound reported earnings per share of ($0.09) during the same quarter last year, which would suggest a negative year-over-year growth rate of 77.8%. The company is scheduled to report its next earnings results on Tuesday, February 20th.

According to Zacks, analysts expect that Mediwound will report full year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.01). For the next year, analysts anticipate that the business will post earnings of ($0.68) per share, with EPS estimates ranging from ($1.16) to ($0.44). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Mediwound.

Mediwound (NASDAQ:MDWD) last posted its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. Mediwound had a negative return on equity of 246.58% and a negative net margin of 904.26%.

A number of analysts have commented on the company. Zacks Investment Research lowered Mediwound from a “hold” rating to a “sell” rating in a report on Thursday. Jefferies Group reissued a “buy” rating and issued a $10.00 target price on shares of Mediwound in a report on Thursday, September 28th. Oppenheimer set a $10.00 target price on Mediwound and gave the stock a “buy” rating in a report on Thursday, November 16th. ValuEngine raised Mediwound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Finally, Cowen assumed coverage on Mediwound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 target price for the company. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.13.

Several institutional investors and hedge funds have recently modified their holdings of MDWD. Wells Fargo & Company MN grew its holdings in shares of Mediwound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after acquiring an additional 12,522 shares during the period. Nationwide Fund Advisors bought a new stake in shares of Mediwound in the third quarter worth $1,538,000. Alyeska Investment Group L.P. bought a new stake in shares of Mediwound in the third quarter worth $2,140,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Mediwound by 9.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock worth $11,882,000 after acquiring an additional 192,860 shares during the period. 29.46% of the stock is owned by institutional investors.

Shares of Mediwound (NASDAQ:MDWD) opened at $4.45 on Friday. The company has a market capitalization of $120.36, a price-to-earnings ratio of -4.54 and a beta of -0.01. Mediwound has a fifty-two week low of $4.15 and a fifty-two week high of $8.25.

ILLEGAL ACTIVITY NOTICE: “” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2018/01/21/1571738.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply